logo
Kentucky Derby Racecourse Renovation Paused Due to ‘Risk Of Significant Inflation'

Kentucky Derby Racecourse Renovation Paused Due to ‘Risk Of Significant Inflation'

Forbes25-04-2025

Churchill Downs' four-year marquee project—announced just two months ago—is already off the burner due to economic uncertainty and a surprising 'hesitancy' in ticket sales for its marquee race.
Mystik Dan #3, ridden by jockey Brian J. Hernandez Jr. (R), crosses the finish line ahead of Sierra ... More Leone #2, ridden by jockey Tyler Gaffalione and Forever Young, ridden by jockey Ryusei Sakai to win the 150th running of the Kentucky Derby at Churchill Downs last year. (Photo by Michael Reaves)
The parent company of the Kentucky Derby racetrack is temporarily pausing a $920 million four-year expansion of the iconic horseracing venue due to 'increased general economic uncertainty and risk of significant inflation' driven by President Trump's tariffs, which 'has created unanticipated and currently unquantifiable expected cost increases in most materials,' William Carstanjen, CEO of Churchill Downs Inc., told investors on an earnings call Thursday.
The project was first announced in the company's previous quarterly financial report in February, but 'a lot has changed in the world in the past nine weeks since that earnings call, including increased general economic uncertainty and risk of significant inflation,' Carstanjen told Wall Street analysts.
The Louisville-based gambling and racing company made the announcement as it released first-quarter earnings, which were overall positive with record net revenue up 9% compared to the same period in 2024.
'Derby is their number one asset, and they just don't want to use shareholder capital at the wrong time, particularly when their stock price is where it is,' Chad Beynon, a senior analyst covering gaming, lodging and theaters for Macquarie Capital, told Forbes.
Shares of Churchill Downs cratered 16% since Thursday's earnings announcement, and are down 33% year to date.
On Churchill Downs' earnings call in late February, the company announced the nearly $1 billion four-year project, which included tearing down and rebuilding the racetrack's Skye Terrace, building new permanent infield venues for premium ticket holders and upgrading amenities for general admissions guests. But President Donald Trump's tariffs have 'created unanticipated and currently unquantifiable expected cost increases in most materials,' Carstanjen told investors. Consequently, Churchill Downs is pausing the project 'to let things settle down so that we can better determine any permanent changes in the cost of this project and better evaluate any changes in the overall economic environment.' Company executives told Wall Street analysts the pause 'could literally mean a quarter or it could mean several quarters,' Beynon said. 'So I think they're just being very disciplined, where this project will get done at some point.'
$210.7 million. That was the record amount bet on the 2024 Kentucky Derby race, representing roughly two-thirds of the record $320.5 million wagered on all the races run at Churchill Downs on derby day.
'Year-over-year growth for the event ticket sales subindustry decelerated by approximately 10 percentage points between April 2nd and April 19th, suggesting that consumers are tightening their wallets when it comes to this expensive, very discretionary area—at least for the time being,' Michael Gunther, VP and head of insights at Consumer Edge, told Forbes. His firm analyzes credit and debit card data to track event ticket sales through platforms like Ticketmaster, Stubhub, Seatgeek, Axs, Front Gate, among others. 'The step-down in growth after April 2nd's larger-than-expected tariff announcement is notable, with continued economic uncertainty continuing to pressure spending.'
Whether in an environment of reduced discretionary spending, the Derby will draw the enormous crowds it has historically. 'In 2025, in my opinion, [we] took a little bit of a jolt because we didn't have the endless pool of demand that we've seen in prior years,' Carstanjen told investors, noting some 'hesitancy' in sales, particularly for lower-tier tickets, which he pointed out are 'not inexpensive tickets, call them $1,000-plus tickets.' In a note to investors, Beynon wrote: 'For the Kentucky Derby this year, [Churchill Downs] management expects roughly flat EBITDA; recall that this is comping against an impressive $30 million EBITDA increase from last year's Kentucky Derby.'
What's On The Kentucky Derby Menu? Chef Robert Lopez Breaks It Down (Forbes)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why are Tata Motors shares falling nearly 5% today? Know More
Why are Tata Motors shares falling nearly 5% today? Know More

Business Upturn

time10 minutes ago

  • Business Upturn

Why are Tata Motors shares falling nearly 5% today? Know More

By Aditya Bhagchandani Published on June 16, 2025, 09:42 IST Shares of Tata Motors Ltd plunged over 4.6% to ₹679.15 on Monday, June 16, after Jaguar Land Rover (JLR) issued a weaker-than-expected financial outlook for FY26 during its latest investor presentation. The stock opened lower and continued to slide, touching an intraday low of ₹679.10. Tata Motors' UK-based luxury car subsidiary JLR stated that it now expects its EBIT margin for FY26 to be in the range of 5–7%, down sharply from the earlier guidance of 10%. This comes as a disappointment to investors, particularly as the company had reported a strong EBIT margin of 10.7% in Q4FY25. In addition to the margin downgrade, JLR said it anticipates free cash flow to be close to zero in FY26, although it expects year-on-year improvement in FY27 and FY28. The update has raised concerns about the near-term profitability and cash generation of the company's luxury vehicle arm, which has been a key driver of growth in recent quarters. At 9:40 AM, Tata Motors' stock was trading at ₹679.15, down 4.62% from the previous close of ₹712.05. The company's market capitalization stood at ₹2.51 lakh crore. Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information. Ahmedabad Plane Crash Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.

HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation
HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation

Business Wire

time32 minutes ago

  • Business Wire

HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation

TOKYO--(BUSINESS WIRE)--HekaBio K.K. (Headquarters: Chuo-ku, Tokyo; President & CEO: Robert E. Claar; hereinafter 'HekaBio') today announced the signing of a strategic partnership agreement with Alfresa Holdings Corporation (Headquarters: Chiyoda-ku, Tokyo; Representative Director & President: Ryuji Arakawa; hereinafter 'Alfresa Holdings'), the leading pharmaceutical wholesaler group in Japan. As part of this agreement, Alfresa Holdings has also made a capital investment in HekaBio. The partnership aims to accelerate the commercialization of innovative medical products in Japan. HekaBio, Japan-based Biopharma and MedTech Platform, Enters Strategic Partnership with Alfresa Holdings Corporation -- Accelerating Access to Innovative Therapies in Japan through Alfresa Group's 'Total Supply Chain Service'-- Share Background and Purpose In recent years, Japan has implemented policy reforms to address the growing access gap, where innovative therapies approved overseas are slow to come to the Japanese market. In response to these developments, HekaBio has focused on introducing cutting-edge pharmaceuticals, medical devices, and regenerative medicine products from global markets into Japan and the Asia-Pacific markets. Leveraging a proprietary global network and partnership model, HekaBio evaluates over 200 assets annually across oncology, cardiology and CNS, and supports end-to-end commercialization from licensing to clinical and regulatory development, manufacturing and sales. This partnership with Alfresa Group will enable HekaBio to advance and expand its portfolio and impact, particularly in CNS and regenerative medicine where Alfresa Group has strengths in manufacturing and in sales, including various other aspects of sales-related operations across the supply chain. Outlook Through this partnership, HekaBio and Alfresa Group aim to accelerate the introduction of high-impact, potential blockbuster therapies into the Japanese market, expanding treatment options for patients. The companies also plan to explore commercialization strategies across the Asia-Pacific region and beyond. About HekaBio HekaBio is a Japan-based, asset-light healthcare platform that accelerates patient access to global medicines and MedTech across Asia-Pacific. HekaBio reviews over 200 assets annually to in-license a select few, focusing on early-stage, de-risked opportunities in CNS, oncology, and healthy longevity. HekaBio synchronizes U.S. and Japan development timelines and leverages strategic partnerships to optimize commercial success. Japan, the world's third-largest healthcare market, serves as its launchpad for regional expansion. To learn more about HekaBio's mission and portfolio, visit About Alfresa Holdings Alfresa Holdings is the holding company for the Alfresa Group, which operates businesses ranging from the development, manufacture, and distribution of pharmaceuticals to the operation of dispensing pharmacies and is the top corporate group in Japan in terms of ethical pharmaceuticals wholesaling, with consolidated net sales exceeding ¥2.9 trillion in the fiscal year ended March 31, 2025. Guided by its corporate philosophy, 'we create and deliver a fresh life for all,' the entire Group supports supply chains for pharmaceuticals and other products, a form of social infrastructure underpinning Japanese healthcare, contributing to a wide range of medical needs. For more information:

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders
SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

Business Wire

time43 minutes ago

  • Business Wire

SINOVAC Board of Directors Alerts Shareholders to Advantech/Prime Success' New Lawsuit, Which Threatens to Prevent Payment of US$55.00 Special Dividend to All Valid Shareholders

BEIJING--(BUSINESS WIRE)--The Board of Directors of SINOVAC Biotech Ltd. (NASDAQ: SVA) (' SINOVAC ' or the ' Company '), a leading provider of biopharmaceutical products in China, today disclosed that on June 12, 2025, Advantech/Prime Success filed a Petition for Emergency Injunctive Relief against SINOVAC, et al., naming as relief parties Cede & Co., The Depository Trust Company, and Equiniti (the dividend paying agent retained by the SINOVAC Board), which may prevent the SINOVAC Board from paying the US$55.00 special dividend as scheduled on or about July 9, 2025. We learned that Vivo Capital's counsel informed the paying agent that Vivo would challenge the dividend and asked the paying agent to withdraw from facilitating the distribution of the US$55.00 dividend declared by the SINOVAC Board to all valid shareholders. The SINOVAC Board has an obligation to answer this Petition on behalf of all SINOVAC common shareholders to stand up to the egregious actions of Prime Success. We expect to file our Opposition Brief today at 5:00 p.m. Atlantic Standard Time, followed by a hearing on Wednesday, June 18. We continue to be shocked by the self-serving, unnecessary actions by Advantech and Vivo Capital (together known as the 'Dissenting Investor Group') against SINOVAC, threatening the rightful dividend payment to all valid SINOVAC common shareholders. These incomprehensible actions are unacceptable to the SINOVAC Board because: The Dissenting Investor Group has already pocketed more than US$1.1 billion in dividends from SINOVAC's operating subsidiary, while all SINOVAC's valid shareholders received nothing. An amount equal to the aggregate amount of cash that would be payable under the US$55.00 per common share special dividend in respect of the 2018 PIPE shares has been set aside by the SINOVAC Board in an escrow account managed by an independent third party pending final resolution of the legal proceedings, which the Dissenting Investor Group initiated. Thus, there is no risk whatsoever that the Dissenting Investor Group's allocations of the dividend will not be paid if the courts ultimately decide in their favor regarding the PIPE shares. These new actions by the Dissenting Investor Group go against their assertions of their support of the US$55.00 dividend payment in their letters to shareholders and raises the question – how can you trust anything they say in their letters or press releases? The SINOVAC Board will continue to fight these frivolous lawsuits, all of which aim to accomplish one thing: to allow the Dissenting Investor group to double dip on dividends. We feel certain we will prevail quickly in this and other proceedings. The SINOVAC Board is on a mission to restore fairness and deliver value to ALL SINOVAC shareholders. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. Safe Harbor Statement This announcement contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'may,' 'will,' 'expect,' 'anticipate,' 'aim,' 'estimate,' 'intend,' 'plan,' 'believe,' 'potential,' 'continue,' 'is/are likely to' or other similar expressions. Such statements are based upon current expectations and relate to events that involve known or unknown risks, uncertainties and other factors, including without limitation risks, uncertainties and factors related to the timing of filings, hearings and other litigation-related matters, all of which are difficult to predict and many of which are beyond the Company's control, which may cause actual results, performance or achievements to differ materially from those in the forward-looking statements. Further information regarding these and other risks, uncertainties or factors is included in the Company's filings with the U.S. Securities and Exchange Commission. The Company does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under law.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store